**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 68157

**Manuscript Type:** CASE REPORT

**Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report**

Sirch C *et al*. AIP in a renal transplant patient

Cristina Sirch, Niloufar Khanna, Lynda Frassetto, Francesco Bianco, Mary Louise Artero

**Cristina Sirch, Francesco Bianco, Mary Louise Artero,** Nefrologia e Dialisi, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste 34100, Italy

**Niloufar Khanna,** Medicine, California Northstate University, Elk Grove, CA 95757, United States

**Lynda Frassetto,** Internal Medicine, Division of Nephrology, University of California San Francisco, San Francisco, CA 94193, United States

**Author contributions:** Sirch C, Artero ML, and Khanna N contributed equally to this work with regard to diagnosis, obtaining the data, and writing the manuscript; Frassetto L and Bianco F assisted in data analysis and writing of the manuscript; and all authors have read and approved the final manuscript.

**Corresponding author: Cristina Sirch, MD, Doctor,** Nefrologia e Dialisi, Azienda Sanitaria Universitaria Giuliano Isontina, Piazza dell'Ospitale 2, Trieste 34100, Italy. [cristina.sirch@asugi.sanita.fvg.it](mailto:cristina.sirch@asugi.sanita.fvg.it)

**Received:** August 11, 2021

**Revised:** November 16, 2021

**Accepted: January 6, 2022**

**Published online:**

**Abstract**

BACKGROUND

Acute intermittent porphyria (AIP) is an inherited disorder of porphyrin metabolism with a worldwide distribution and a prevalence ranging from 1 to 9 per million population. AIP is caused by an autosomal dominant-inherited mutation of low penetrance resulting in a deficiency of porphobilinogen deaminase (PBGD) activity. Acute attacks are provoked by stressors such as certain medications, alcohol, and infection. We herein present the first case report of AIP detected in a post-renal transplant patient.

CASE SUMMARY

The patient was a 65-year-old man who underwent transplantation 2 years previously for suspected nephroangiosclerosis and chronic interstitial nephropathy. He subsequently developed diabetes mellitus which required insulin therapy. He had been treated in the recent past with local mesalamine for proctitis. He presented with classic but common symptoms of AIP including intense abdominal pain, hypertension, and anxiety. He had multiple visits to the emergency room over a 6-mo period for these same symptoms before the diagnosis of AIP was entertained. His urinary postprandial blood glucose level was 60 mg/24 h (normal, < 2 mg/24 h). He was placed on a high carbohydrate diet, and his symptoms slowly improved.

CONCLUSION

This case report describes a common presentation of an uncommon disease, in which post-transplant complications and medications may have contributed to precipitating the previously undiagnosed AIP. We hypothesize that the low-carbohydrate diet and insulin with which our patient was treated may have led to the attacks of AIP. Alternatively, our patient’s mesalamine treatment for proctitis may have led to an acute AIP crisis. A high index of suspicion is needed to consider the diagnosis of a heme synthesis disorder, which presents with the common symptoms of abdominal pain, high blood pressure, and anxiety.

**Key Words:** Acute intermittent porphyria; Post-transplantation diabetes; Mesalamine; Tacrolimus; Renal transplantation; Case report

Sirch C, Khanna N, Frassetto L, Bianco F, Artero ML. Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report. *World J Transplant* 2022; In press

**Core Tip:** This case report describes a common presentation of an uncommon disease, in which post-transplant complications and medications may have contributed to precipitating his previously undiagnosed acute intermittent porphyria. A high index of suspicion is needed to consider the diagnosis of a heme synthesis disorder, which presents with the common symptoms of abdominal pain, high blood pressure, and anxiety in a post-renal transplantation patient.

**INTRODUCTION**

Acute intermittent porphyria (AIP) is an inherited disorder of porphyrin metabolism with a worldwide distribution and a prevalence ranging from 1 to 9 per million population with the highest prevalence found in northern Europe[1]. AIP is caused by an autosomal dominant inherited mutation of low penetrance resulting in a deficiency of porphobilinogen deaminase (PBGD) activity[1]. Acute attacks are provoked by stressors such as certain medications, alcohol, and infection. Symptoms include abdominal pain mimicking acute surgical abdomen, sometimes leading to unnecessary laparotomy, as well as neuromuscular and psychiatric disturbances. Late-stage associated conditions include renal insufficiency and hepatocellular cancer[2,3].

We present a patient who underwent deceased donor renal transplantation and subsequently developed AIP. Experience of renal transplantation in patients with AIP is limited. We found three previous reports describing renal transplantation[4,5] or combined liver-renal transplantation[6] in patients with a history of known AIP, but none reporting the diagnosis of AIP in a previously transplanted patient.

**CASE PRESENTATION**

***Chief complaints***

Recurrence of abdominal pain, nausea, and vomiting in a kidney transplant patient.

***History of present illness***

A 65-year-old man reported the appearance of rectal blood in March 2017 and visited a proctologist. He started local mesalamine therapy for proctitis, but the drug was discontinued a few days later due to abdominal pain and constipation. During the subsequent 6 mo, he presented several times to the emergency department complaining of severe abdominal pain, nausea, and vomiting. He related an anxious mood and low energy level in addition to tachycardia and an increase in blood pressure which was no longer well-controlled with his usual therapy. He presented to the emergency room eight times for various complaints (Figure 1): Epigastric pain without mention of mesalamine, agitation and anxiety, thoracic pain, abdominal pain, and precordial pain.

***History of past illness***

The patient had been treated for hypertension since 1994 and developed ischemic heart disease. His renal function gradually deteriorated over the years due to suspected nephroangiosclerosis and chronic interstitial nephropathy, as ultrasound examination demonstrated small echogenic kidneys. He started hemodialysis in 2008 and was evaluated for renal transplantation; a left nephrectomy was performed for a small incidental renal carcinoma. The histopathologic examination of the nephrectomy specimen revealed angiosclerosis and tubulointerstitial fibrosis. He underwent a deceased-donor kidney transplant in 2015, for which he was treated with tacrolimus, mycophenolate mofetil, and methylprednisolone. He developed diabetes mellitus post-transplant and insulin therapy was initiated (see Table 1).

***Personal and family history***

The patient had no known family history of porphyria.

***Physical examination***

The patient was hemodynamically stable with a heart rate of 90 bpm and blood pressure of 160/90 mmHg, but appeared in mild distress. The physical examination revealed an intermittently tender, non-distended abdomen with normal bowel sounds and absent rigidity, rebound, and guarding. The remainder of the physical examination was unremarkable.

***Laboratory examinations***

Serum levels of hemoglobin, electrolytes, hepatic transaminases, amylase, thyroid function, protein electrophoresis, and C-reactive protein were normal, as was the urine analysis. Renal function was stable with a serum creatinine of 1.2 mg/dL; the urine culture was negative.

***Imaging examinations***

Plain X-rays of the abdomen showed distended colon and fecal impaction, and ultrasound revealed that the liver, spleen, pancreas, and transplanted kidney were of normal size and consistency and that the site of the left nephrectomy was occupied by intestinal loops.

**FINAL DIAGNOSIS**

Based on the clinical symptoms and the radiologic and laboratory findings, a diagnosis of porphyria was attained. The level of postprandial blood glucose (PBG) in a 24-h urine sample was determined utilizing spectrophotometric technique (ClinRep for the porphyrins and ClinEasy for PBG; RECIPE Chemicals and Instruments, Munich, Germany). The level of PBG was significantly elevated to - 60 mg/24 h in the first sample (normal value, < 2 mg/24 h), whereas the values for porphyrins and coproporphyrins were negative, supporting the hypothesis of AIP (Figure 2).

**TREATMENT**

After AIP was confirmed, treatment was initiated with a carbohydrate-rich diet, and the patient's symptoms slowly improved. The timeline of events is listed in Figure 1.

The patient was referred to the genetics division for analysis of the PBGD (also known as the hydroxymethylbilane synthase) gene and also splicing variants using sequencing and polymerase chain reaction amplification, but tested negative for the most common available single nucleotide polymorphisms (SNPs). It is notable that the patient’s insulin requirements did not change after the high-carb diet was started; his insulin doses, glycated hemoglobin, and glucose levels did not change.

**OUTCOME AND FOLLOW-UP**

The patient's symptoms slowly improved with a carbohydrate-rich diet.

**DISCUSSION**

To our knowledge, this is the first report of new onset AIP symptomatology in a renal transplant patient. We hypothesize that our patient had pre-existing but undetected AIP, and that he may have a genetic predisposition due to his European ancestry. Although Lazareth *et al*[7] have reported improved AIP outcomes following renal transplantation, the hepatic origin of the disease may present a risk of acute attack in case of post-transplant complications, medications, infection, or reduced carbohydrate intake.

As mentioned in the History of Past Illness section, the nephrectomy specimen, in addition to the small renal carcinoma, revealed chronic tubulointerstitial lesions and nephroangiosclerosis. According to Pallet *et al*[8], in a large cohort of patients with porphyria-associated kidney disease, kidney biopsies revealed “diffuse glomerulosclerosis and chronic interstitial changes”, and thus it is conceivable that the AIP was responsible for the renal insufficiency in the native kidneys. On the other hand, these findings are very common and nonspecific in nephropathy patients, and may not accurately reflect the etiology of the renal disease.

Over 500 PBGD mutations have been described in AIP. Penetrance is incomplete, and less than 10 per cent of individuals with each genetic defect may have phenotypic expression of the disease[9]. The enzyme deficiency alone is not sufficient to trigger crises; environmental factors are required. Thus, 80%-90% of those with the enzyme deficiency never manifest symptoms[10]. Acute attacks are often precipitated by drugs such as barbiturates and other anticonvulsants, calcium channel blockers, sedatives, antibiotics, hormones, alcohol, tobacco, calorie-restricted or low carbohydrate diets, infection, surgery, psychological disorders, or other comorbid conditions. In some patients, no precipitating stressor is found[11].

The diagnosis of acute porphyria is challenging - symptoms are not specific and may mimic various digestive and neuropsychiatric diseases. Very intense, diffuse abdominal pain is often the earliest characteristic symptom. Nausea, vomiting, constipation, urinary retention, arrhythmias, labile blood pressure, and hyponatremia may coincide with the pain[11]. The AIP crisis may also have associated neurological complications such as respiratory arrest due to bulbar involvement, quadriplegia, neuropathic limb pain, depression, and suicide[12]. In the present case, the patient presented with the principal signs and symptoms of AIP: Very intense abdominal pain, hypertension, and anxiety/depression disorder.

The clinical criteria for AIP diagnosis include the paroxysmal nature of the symptoms, while the biochemical criteria include a more than fivefold increase in urinary porphobilinogen excretion, which is also elevated in 88% of AIP patients in remission. DNA analysis of the PBGD gene is the most reliable diagnostic method.

Current treatment options include heme preparations during an acute attack; intravenous glucose 10% alone (see discussion below) - at least 300 g daily - may resolve mild attacks or may be given while waiting for heme arginate to be available. During acute attacks, correction of dehydration and electrolyte imbalances as well as monitoring of vital capacity and expiratory flow rate is important. This patient responded to a high complex carbohydrate diet. No variation of the immunosuppressive protocol has been required.

A high prevalence of AIP among the Spanish population has been reported, and variations on the CYP2D6 enzyme, important for hepatic drug metabolism, in this population may impact the penetrance of this disorder in those with a PBGD enzyme mutation[13]. Additionally, G6PD deficiency is common among Mediterranean populations[14], and the levels of G6PD can affect AIP exacerbations[15]. Although our patient tested negative for the most common SNPs, with over 500 mutations identified affecting the *PBGD* gene[16]which can cause AIP, it is possible that our patient had a rarer or undescribed mutation.

Aminolaevulinic acid synthase is the first enzyme in the heme synthesis pathway (see Figure 2 for details of the heme synthesis pathway) and is regulated by glucose and heme, such that high levels of glucose inhibit heme synthesis and prevent attacks of AIP. Although AIP is caused by a defect in the third enzyme of the heme synthesis pathway (PBGD), stimulation of aminolevulinate synthase by decreased glucose leads to activation of the heme synthesis pathway and causes an acute attack of AIP. Increased glucose, including glucose infusions and avoidance of fasting between attacks, has been shown to be beneficial in the management of AIP[17]. The American Porphyria Foundation suggests a 55%-60% carb-based diet for patients with AIP and cautions against fasting or crash-dieting[18]. This patient recovered upon being placed on a high-carb diet, supporting the hypothesis that a low-glucose state triggered his attack.

It is possible that the patient’s diabetes combined with his low carbohydrate intake resulted in low uptake of glucose into the cells, mimicking the fasting state known to trigger AIP attacks[11]. Post-transplant diabetes is commonly induced by tacrolimus treatment through decreased insulin secretion, increased insulin resistance, and beta-islet cell toxicity[19]. A case report of a patient with hereditary coproporphyria showed that high levels of tacrolimus triggered an acute attack and that the patient’s symptoms resolved once tacrolimus levels were lowered into the therapeutic range, thereby suggesting a role for tacrolimus in precipitation of AIP attacks[20].On the other hand, hyperinsulinism may be associated with clinically stable AIP[21].

Mouse models of AIP show key differences in glucose metabolism between AIP and non-AIP mice. There are also differences in the level of enzymes in the pentose-phosphate pathway and glutathione metabolism, which can lead to decreased hepatic glucose and exacerbate AIP. AIP mice have been shown to rely more on gluconeogenesis and fatty acid metabolism for maintaining blood glucose levels as compared to control mice, which rely more on glycogen metabolism[22].

Although medications are a common trigger for AIP, the patient was not taking any medications commonly known to cause AIP. He was transiently treated with mesalamine, although the Norwegian Porphyria Center website[23],which serves as a clearinghouse for information on drug “porphyrinogenicity”~~,~~ indicates that mesalamine has low porphyrinogenic potential. In addition, the patient’s symptoms continued several months after stopping the drug. The patient had not been exposed to other new drugs, had not undergone surgery, and had no recent infections during this time, rendering this etiology less likely.

**CONCLUSION**

We present an older subject with a common presentation of an uncommon disease, whose post-transplant complications and medications may have contributed to precipitating his previously undiagnosed AIP. A high index of suspicion is needed to consider the possibility of a heme synthesis disorder, which presents with the common symptoms of abdominal pain, high blood pressure, and anxiety, in renal transplant patients.

**REFERENCES**

1 **Ramanujam VS**, Anderson KE. Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias. *Curr Protoc Hum Genet* 2015; **86**: 17.20.1-17.20.26 [PMID: 26132003 DOI: 10.1002/0471142905.hg1720s86]

2 **García-Morillo JS**, González-Estrada A, Rodriguez-Suarez S. [Influence of long-term treatment with hemin in the development of chronic renal failure in acute intermittent porphyria]. *Med Clin (Barc)* 2016; **146**: 373-374 [PMID: 26723937 DOI: 10.1016/j.medcli.2015.10.033]

3 **Peoc'h K**, Manceau H, Karim Z, Wahlin S, Gouya L, Puy H, Deybach JC. Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. *Mol Genet Metab* 2019; **128**: 236-241 [PMID: 30413387 DOI: 10.1016/j.ymgme.2018.10.001]

4 **Warholm C**, Wilczek H. Renal transplantation in a case of acute intermittent porphyria. *J Clin Pharmacol* 2003; **43**: 1158-1160 [PMID: 14517198 DOI: 10.1177/0091270003257223]

5 **Turton-Weeks S**, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR, Anderson KE. Pretransplant evaluation of a patient with acute intermittent porphyria. *Prog Transplant* 2001; **11**: 214-216 [PMID: 11949465 DOI: 10.7182/prtr.11.3.61965k72uq73v0vx]

6 **Wahlin S**, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG. Combined liver and kidney transplantation in acute intermittent porphyria. *Transpl Int* 2010; **23**: e18-e21 [PMID: 20028496 DOI: 10.1111/j.1432-2277.2009.01035.x]

7 **Lazareth H**, Talbi N, Kamar N, Levi C, Moulin B, Caillard S, Frimat L, Chemouny J, Chatelet V, Vachey C, Snanoudj R, Lefebvre T, Karras A, Gouya L, Schmitt C, Puy H, Pallet N. Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. *Mol Genet Metab* 2020; **131**: 259-266 [PMID: 32893121 DOI: 10.1016/j.ymgme.2020.08.004]

8 **Pallet N**, Karras A, Thervet E, Gouya L, Karim Z, Puy H. Porphyria and kidney diseases. *Clin Kidney J* 2018; **11**: 191-197 [PMID: 29644058 DOI: 10.1093/ckj/sfx146]

9 **Chen B**, Solis-Villa C, Hakenberg J, Qiao W, Srinivasan RR, Yasuda M, Balwani M, Doheny D, Peter I, Chen R, Desnick RJ. Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease. *Hum Mutat* 2016; **37**: 1215-1222 [PMID: 27539938 DOI: 10.1002/humu.23067]

10 **Szlendak U**, Bykowska K, Lipniacka A. Clinical, Biochemical and Molecular Characteristics of the Main Types of Porphyria. *Adv Clin Exp Med* 2016; **25**: 361-368 [PMID: 27627571 DOI: 10.17219/acem/58955]

11 **Pischik E**, Kauppinen R. An update of clinical management of acute intermittent porphyria. *Appl Clin Genet* 2015; **8**: 201-214 [PMID: 26366103 DOI: 10.2147/TACG.S48605]

12 **González-Arriaza HL**, Bostwick JM. Acute porphyrias: a case report and review. *Am J Psychiatry* 2003; **160**: 450-459 [PMID: 12611823 DOI: 10.1176/appi.ajp.160.3.450]

13 **Barreda-Sánchez M**, Buendía-Martínez J, Glover-López G, Carazo-Díaz C, Ballesta-Martínez MJ, López-González V, Sánchez-Soler MJ, Rodriguez-Peña L, Serrano-Antón AT, Gil-Ferrer R, Martínez-Romero MDC, Carbonell-Meseguer P, Guillén-Navarro E. High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor. *Orphanet J Rare Dis* 2019; **14**: 59 [PMID: 30808393 DOI: 10.1186/s13023-019-1031-7]

14 **Kurdi-Haidar B**, Mason PJ, Berrebi A, Ankra-Badu G, al-Ali A, Oppenheim A, Luzzatto L. Origin and spread of the glucose-6-phosphate dehydrogenase variant (G6PD-Mediterranean) in the Middle East. *Am J Hum Genet* 1990; **47**: 1013-1019 [PMID: 1978555]

15 **Faut M**, Paiz A, San Martín de Viale LC, Mazzetti MB. Alterations of the redox state, pentose pathway and glutathione metabolism in an acute porphyria model. Their impact on heme pathway. *Exp Biol Med (Maywood)* 2013; **238**: 133-143 [PMID: 23390166 DOI: 10.1177/1535370212473702]

16 **Schneider-Yin X**, Hergersberg M, Schuurmans MM, Gregor A, Minder EI. Mutation hotspots in the human porphobilinogen deaminase gene: recurrent mutations G111R and R173Q occurring at CpG motifs. *J Inherit Metab Dis* 2004; **27**: 625-631 [PMID: 15669678 DOI: 10.1023/b:boli.0000042936.20691.ad]

17 **Handschin C**, Lin J, Rhee J, Peyer AK, Chin S, Wu PH, Meyer UA, Spiegelman BM. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. *Cell* 2005; **122**: 505-515 [PMID: 16122419 DOI: 10.1016/j.cell.2005.06.040]

18 **Bonkovsky HL,** Philip J. Diet Information for All Porphyrias. American Porphyria Foundation. [cited 8 August 2021]. Available from: https://porphyriafoundation.org/for-patients/diet-and-nutrition/diet-information-for-all-porphyrias/

19 **Shivaswamy V**, Boerner B, Larsen J. Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. *Endocr Rev* 2016; **37**: 37-61 [PMID: 26650437 DOI: 10.1210/er.2015-1084]

20 **Telkes G**, Pusztai A, Földes K, Langer RM. Kidney transplantation in hereditary coproporphyria using tacrolimus and mycophenolate mofetil: a case report. *Transplant Proc* 2013; **45**: 3703-3704 [PMID: 24315002 DOI: 10.1016/j.transproceed.2013.10.008]

21 **Solares I**, Izquierdo-Sánchez L, Morales-Conejo M, Jericó D, Castelbón FJ, Córdoba KM, Sampedro A, Lumbreras C, Moreno-Aliaga MJ, Enríquez de Salamanca R, Berraondo P, Fontanellas A. High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach. *Biomedicines* 2021; **9** [PMID: 33807619 DOI: 10.3390/biomedicines9030255]

22 **Collantes M**, Serrano-Mendioroz I, Benito M, Molinet-Dronda F, Delgado M, Vinaixa M, Sampedro A, Enríquez de Salamanca R, Prieto E, Pozo MA, Peñuelas I, Corrales FJ, Barajas M, Fontanellas A. Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency. *Hum Mol Genet* 2016; **25**: 1318-1327 [PMID: 26908609 DOI: 10.1093/hmg/ddw013]

23 **Helse Bergen**.Nasjonalt Kompetansesenter for Porfyrisykdommer (NAPOS). [cited 8 August 2021]. Available from: https://helse-bergen.no/nasjonalt-kompetansesenter-for-porfyrisykdommer-napos

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this case report.

**Conflict-of-interest statement:** None of the authors report a conflict of interest concerning this case report.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** August 11, 2021

**First decision:** October 27, 2021

**Article in press:**

**Specialty type:** Transplantation

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** de Carvalho JF, Fontanellas A, Liang P **S-Editor:** Wang JJ **L-Editor:** Wang TQ **P-Editor:**

**Figure Legends**



**Figure 1 Heme synthesis pathway.** 1Mitochondrial enzyme.



**Figure 2 Timeline of patient symptoms and response to treatment.** ER: Emergency room; AIP: Acute intermittent porphyria.

**Table 1 Medications used**

|  |  |  |
| --- | --- | --- |
| **Medication list** | **Dose** | **Time** |
| Tacrolimus | 0.5 mg; 0.5 mg | 08:00; 20:00 |
| Mycophenolate mofetil | 1000 mg; 500 mg | 08:00; 20:00 |
| Methylprednisolone | 2 mg | 08:00 |
| Aspirin | 100 mg | 13:00 |
| Ranitidine | 300 mg | 08:00 |
| Cinacalcet | 30 mg | 08:00 |
| Bisoprolol | 5 mg | 08:00 |
| Amlodipine | 10 mg | 20:00 |
| Nitroglycerin TTS | 10 mcg | 1 d |
| Atorvastatin | 40 mg | 20:00 |
| Calcitriol | 0.25 mcg | 08:00 |
| Na bicarbonate | 1000 mg qd |  |
| Insulin |  |  |
| Bromazepam | 2.5 mg/mL 5 drops bid |  |

TTS: Transdermal therapeutic system.